Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of aspirin resistance: 81 mg once daily vs 81 mg twice daily in splenectomized thalassemia patients
TCTR20260723007Phase 3Active, not recruiting
- Sponsor
- -
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aspirin in Thalassaemia, sponsored by -. Started Jun 2026; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
Thalassaemia
Beyond the preview
Go deeper on TCTR20260723007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260723007.